Aditxt, Inc. Increase (Decrease) in Deposit Assets
Aditxt, Inc. (ADTX) reported Increase (Decrease) in Deposit Assets of -$26.09 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDepositOtherAssets · last filed 2026-05-20
- Aditxt, Inc. increase (decrease) in deposit assets for the quarter ending 2025-12-31 was -$183.11K.
- Aditxt, Inc. increase (decrease) in deposit assets for the quarter ending 2025-09-30 was $28.75K.
- Aditxt, Inc. increase (decrease) in deposit assets for the quarter ending 2025-06-30 was $36.10K.
- Aditxt, Inc. increase (decrease) in deposit assets for the quarter ending 2025-03-31 was $92.17K, a 253.35% increase year-over-year.
- Aditxt, Inc. increase (decrease) in deposit assets for fiscal 2025 was -$26.09K.
- Aditxt, Inc. increase (decrease) in deposit assets for fiscal 2024 was -$18.74K.
- Aditxt, Inc. increase (decrease) in deposit assets for fiscal 2023 was -$248.96K.
- Aditxt, Inc. increase (decrease) in deposit assets for fiscal 2020 was $72.30K.
| Period end | Increase (Decrease) in Deposit Assets 3 month | Increase (Decrease) in Deposit Assets 6 month | Increase (Decrease) in Deposit Assets 9 month | Increase (Decrease) in Deposit Assets 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$183.11K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$154.36K derived: sum of 2 quarters · filed 2026-03-31 | -$118.26K derived: sum of 3 quarters · filed 2026-03-31 | -$26.09K 10-K · filed 2026-03-31 |
| 2025-09-30 | $28.75K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-18 | $64.85K derived: sum of 2 quarters · filed 2025-11-18 | $157.03K 10-Q · filed 2025-11-18 | $142.66K derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-06-30 | $36.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $128.27K 10-Q · filed 2025-08-14 | $113.90K derived: sum of 3 quarters · filed 2026-05-20 | $108.96K derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-03-31 | $92.17K 10-Q · filed 2026-05-20 | $77.80K derived: sum of 2 quarters · filed 2026-05-20 | $72.86K derived: sum of 3 quarters · filed 2026-05-20 | $47.35K derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | -$14.37K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$19.31K derived: sum of 2 quarters · filed 2026-03-31 | -$44.82K derived: sum of 3 quarters · filed 2026-03-31 | -$18.74K 10-K · filed 2026-03-31 |
| 2024-09-30 | -$4.94K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-18 | -$30.45K derived: sum of 2 quarters · filed 2025-11-18 | -$4.37K 10-Q · filed 2025-11-18 | -$210.22K derived: sum of 4 quarters · filed 2025-11-18 |
| 2024-06-30 | -$25.51K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $572.00 10-Q · filed 2025-08-14 | -$205.28K derived: sum of 3 quarters · filed 2025-08-14 | -$180.28K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $26.09K 10-Q · filed 2025-05-15 | -$179.77K derived: sum of 2 quarters · filed 2025-05-15 | -$154.77K derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | -$205.85K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$180.85K derived: sum of 2 quarters · filed 2025-03-31 | -$248.96K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18 | -$43.10K 10-Q · filed 2024-11-18 | ||
| 2023-06-30 | -$68.10K 10-Q · filed 2024-08-19 | |||
| 2021-06-30 | $199.54K 10-Q · filed 2021-08-12 | |||
| 2020-12-31 | $72.30K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |